echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Drug Ming biology and novel coronavirus antibody Vir reach global R & D cooperation

    Drug Ming biology and novel coronavirus antibody Vir reach global R & D cooperation

    • Last Update: 2020-02-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    25 novel coronavirus and Biotech Corp Vir Biotechnology (hereinafter referred to as Vir) announced that the two sides reached a cooperation agreement for the development and production of the whole human monoclonal antibody for the treatment of new coronavirus pneumonia (COVID-19)

    Covid-19 is caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2)

    According to the terms of the agreement, the two parties will jointly promote the clinical development, production and commercialization of the leading antibody of vir in the treatment of covid-19

    Yao Ming biology will support the development of antibody cell line, technology and preparation, as well as the early production of clinical development

    Once these antibodies are approved by the regulatory authorities, the company will have the right to commercialize related products in Greater China, and the right to commercialize products in other global markets will be owned by vir

    VIR has successfully isolated and identified several monoclonal antibodies binding to sars-cov-2 from survivors of SARS infection

    Further research is underway to determine whether these antibodies or other recognizable antibodies can effectively treat and / or prevent sars-cov-2

    "We are very clear about the importance of rapid response in the fight against covid-19," said Dr

    George A

    scangos, chief executive officer of vir

    "If effective antibody therapy can be developed, cooperation with pharmacobiology will maximize the progress of this research and development and overcome this global disease challenge as early as possible." "Yaoming biology and vir agree that it is urgent to promote the clinical application of covid-19 antibody and benefit patients all over the world as soon as possible

    With the world's leading biomedical development platform and a strong global supply network of biomedical drugs, we will make a unique contribution to accelerating the development and production process of covid-19 antibody therapy, "said Dr

    Chen Zhisheng, CEO of YaoMing bio." this cooperation once again shows that Yaoming bio is working with global biotechnology companies to accelerate the development process of biomedical drugs and benefit global diseases "Yes."
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.